Galmed Pharmaceuticals Ltd. (GLMD) Q2 2021 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day and welcome to GalMed conference call to discuss financial results for the second quarter 2021. Today's conference is being recorded. Before we begin, please note that we will be making certain forward-looking statements on today's call, including those regarding financial results, statements and forecasts regarding anticipated timelines and expectations with respect to our regulatory and clinical development programs, as well as other statements that relate to future events. These statements are based on the beliefs and the expectations of the management of today and actual results, trends, timelines and projections relating to our financial position and projected development programme and pipeline could differ materially. We urge all investors to read carefully the risks and uncertainties disclosed in our filings with the SCEC, including without limitations the risks under the heading risk factors described in our annual report on form 20F filed with the SEC and the risks and uncertainties included in the form 6K filed with the SEC earlier today. GALMED assumes no obligation to update any forward-looking statements or information which speak as of the respective dates only. I would now like to turn the conference over to Alan Beharif, President and Chief Executive Officer. Alan, please go ahead. Thank you, Emma. Good morning, and thank you for joining us on today's conference call. I'm pleased to be here today with our Chief Scientific Officer, Dr. Liat Hayardeni, and our Chief Financial Officer, Bokhai Stensler, to provide you with an update on our clinical development programs, as well to report to you on our financial results for the second quarter of 2021. As always, we'll be happy to take any questions you may have at the conclusion of our prepared re...